Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted therapies are being investigated as potentially more efficacious and tolerable alternatives for this multiply-relapsing disease. Based on promising activity with rituximab and lenalidomide in previously untre...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Ujjani, Chaitra S., Jung, Sin-Ho, Pitcher, Brandelyn, Martin, Peter, Park, Steven I., Blum, Kristie A., Smith, Sonali M., Czuczman, Myron, Davids, Matthew S., Levine, Ellis, Lewis, Lionel D., Smith, Scott E., Bartlett, Nancy L., Leonard, John P., Cheson, Bruce D.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2016
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5123195/
https://ncbi.nlm.nih.gov/pubmed/27697771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-718106
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items